Focal Hand Dystonia Clinical Trial
Official title:
Impact Of Physiotherapy And Botulinum Toxin Type-A In Improving Functional Outcomes In Upper Limb Focal Dystonia Among Post Stroke Patients
Verified date | September 2018 |
Source | Isra University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study was conducted to assess the combine role of Physiotherapy by providing task specific trainings and Botulinum Toxin Type A in improving the functional outcomes of upper limb in post stroke patients with focal hand dystonia.
Status | Completed |
Enrollment | 39 |
Est. completion date | December 2016 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Patients having first episode of unilateral stroke - At least 6 months of post stroke duration presenting with post stroke focal dystonia of the upper limb. - No previous exposure of the affected hand of Botox. - Reduced upper limb functions - Both genders will be included equally. Exclusion Criteria: - Significant speech or cognitive impairment which impedes the ability to perform the assessment. - Other significant upper limb impairment e.g. fracture or frozen shoulder within 6 months. - Severe arthritis, amputation, evidence of fixed contracture, pregnancy or lactating womens. - Other diagnosis likely to interfere with rehabilitation or outcome assessments, e.g. blind, malignancy, - Other conditions which may contribute to upper limb spasticity, e.g. multiple sclerosis, cerebral palsy. - Use of botulinum toxin to the upper limb in the previous 4 months. - Contraindications to intramuscular injection. - Contraindications /allergy to botulinum toxin type A, which include bleeding disorders, myasthenia gravis and concurrent use of aminoglycosides. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Isra University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Action Research Arm Test (ARAT): | It assessed specific changes in limb function by 19 items grouped in four subscales. The total score ranged from 0 to 57. The lower score indicated no movement and upper score indicated normal performance of the patient. | 12 weeks | |
Primary | MOTOR ASSESSMENT SCALE (MAS) | It was a performance-based scale, based on a task-oriented approach to evaluate and assesses performance of functional tasks rather than isolated patterns of movement. All items were assessed using a 7-point scale from 0 - 6. A score of 6 indicated optimal motor behavior. | 12 weeks | |
Primary | WOLF MOTOR FUNCTION TEST (WMFT) | It quantified motor ability through timed functional tasks. It used a 6-point ordinal scale with "0" = "does not attempt with the involved arm" to "5" = movement appears to be normal." | 12 weeks | |
Primary | FUGL- MEYER ASSESSMENT TEST | It was a performance-based impairment index to measure motor functioning. The total score possible was from 0 - 66, with higher function showing the improved level of independence | 12 weeks | |
Secondary | Severity Of Dystonia | The Arm Dystonia Disability Scale: The severity of dystonia was assessed using 0 (None) to 3 (Marked Difficulty in performing activity | 12 weeks | |
Secondary | Stroke Specific Quality Of Life | The stroke specific Quality Of Life was administered to patients which rated their Quality of life | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00376753 -
Muscle Contraction in Patients With Focal Hand Dystonia
|
N/A | |
Completed |
NCT00325091 -
Long-Term Motor Learning in Focal Hand Dystonia
|
||
Recruiting |
NCT00579033 -
Somatosensory Processing in Focal Hand Dystonia
|
N/A | |
Completed |
NCT00106782 -
Transcranial Electrical Polarization to Treat Focal Hand Dystonia
|
Phase 2 | |
Recruiting |
NCT03977493 -
IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia
|
Phase 3 |